Monoclonal antibodies (MAbs) against tumor-associated...

Details Monoclonal antibodies (MAbs) against tumor-associated... Monoclonal antibodies (MAbs) against tumor-associated...

2005-08-09

2005-08-09

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S138100, C424S141100, C424S174100, C424S178100, C424S181100, C435S069600, C530S387100, C530S387300, C530S387700, C530S388100, C530S388200, C530S388800, C530S391100, C530S391700

Reexamination Certificate

active

06926896

ABSTRACT:
The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.

REFERENCES:
patent: 3862925 (1975-01-01), Sarantakis et al.
patent: 4331647 (1982-05-01), Goldenberg et al.
patent: 4349528 (1982-09-01), Koprowski et al.
patent: 4444744 (1984-04-01), Goldenberg
patent: 4446240 (1984-05-01), Nerenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4485093 (1984-11-01), Schlom et al.
patent: 4522918 (1985-06-01), Trowbridge
patent: 4569788 (1986-02-01), Mulshine et al.
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 4582797 (1986-04-01), Trowbridge
patent: 4585742 (1986-04-01), Bernal
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4612282 (1986-09-01), Schlom et al.
patent: 4645828 (1987-02-01), Twardzik et al.
patent: 4677058 (1987-06-01), Tryggvason et al.
patent: 4683200 (1987-07-01), Hirohashi et al.
patent: 4810781 (1989-03-01), Hollinshead
patent: 6294172 (2001-09-01), Bosslet et al.
patent: 3329184 (1985-02-01), None
patent: 3329184 (1985-02-01), None
patent: A 0118365 (1975-09-01), None
patent: A 0098162 (1984-01-01), None
patent: 0 141 079 (1985-05-01), None
patent: A0141079 (1985-05-01), None
patent: 0145373 (1985-06-01), None
patent: 0151030 (1985-08-01), None
patent: A0153114 (1985-08-01), None
patent: A0160446 (1985-11-01), None
patent: 0160897 (1985-11-01), None
patent: 0171083 (1986-02-01), None
patent: 0189849 (1986-08-01), None
patent: A-0213581 (1987-03-01), None
patent: 0268468 (1988-05-01), None
patent: 0 268 468 (1988-05-01), None
patent: 0 365 209 (1990-04-01), None
patent: 0 368 684 (1990-05-01), None
patent: 0 411 893 (1991-02-01), None
patent: 1193378 (1970-05-01), None
patent: WO-A8101469 (1981-05-01), None
patent: WO 88/02117 (1988-03-01), None
Waiduam, T (1991) Science 252: 1657-1662.
ATCC Catalog (7th ed.; 1992) R. Hay et al, “Turner Index”, pp. 485-491.
Sun et al (1987) Proc. Nat'l Acad Sci 54:214-218.
Shaw et al (1987) J. Immunol. 12 138: 4534-4538.
Sakagan et al (1986) J. Immunol. 137: 1066-1074.
Hnatowick et al (1983) Science 220: 613-615.
Gallagher et al (1986) J. Surg. Res. 40: 159-166.
Vitetta et al (1987) Science 238: 1098-1104.
Bosslet et al (1956) Cancer Immunol Immunother. 23: 185-191.
Bosslet et al (1959) Cancer Immunol Immunother. 29: 171-178.
Chung et al (1987) Cancer 60: 1636-1643.
Steplewski et al (1988) PNAS 85: 4852-4856.
Colcher et al (1989) Cancer Res. 49: 1738-1745.
Reichmann et al. (1988) Nature 332: 323-327.
Talalay, P., et al., “Chromogenic Substrates, II. Phenolphthalein Glucuronic Acid as Substrate for the Assay of Glucuronidase Activity,” J. Biol. Chem., 166:757-772 (1946).
Conchie, J., et al., “Mammalian Glycosidases, Distribution in the Body,” Biochem., 71:318-325 (1959).
Davies, P., et al., “The Quantitative Estimation of Pinocytosis Using Radioactive Coloidal Gold,” Biochemical and Biophysical Research Communications, 52(2):627-634 (1973).
Lieber, M. et al., Establishment of a Continuous Tumor-Cell Line (PANC-1) From a Human Carcinoma of the Exocrine Pancreas, Int. Cancer, 15:741-747 (1975).
Bosslet, K., et al., “Monoclonal Murine Antibodies with Specificity for Tissue Culture Lines of Human Squamous-Cell Carcinoma of the Lung,” Cancer Detection and Prevention, 6:181-184 (1983).
Herlyn, D., et al., “Inhibition of Human Tumor Growth by IgG2a Monoclonal Antibodies Correlates with Antibody Density on Tumor Cells,” J. Immunology, 134(2):1300-1304 (Feb. 1985).
Brown J., et al., “A Microassay for Antibody Binding to Tumor Cell Surface Antigens Using125-Labelled Protein A from Staphylococcus Aureus,” J. Immunological Methods, 15:57-66 (1977).
Heyderman, E., “Immunoperoxidase Technique in Histopathology: Applications, Methods and Controls,” J. Clinical Pathology, 32:971-978 (1979).
Bosslet, K., et al., “Molecular Characteristics of Two Lung Carcinoma Cell-Line Associated Membrane Antigens,” Behring Inst. Mitt, 74:27-34 (1984).
Meeting Highlights, “Breast Cancer, Epithelial Cells, and Extracellular Matrix,” JNCI, 73(4):9099-1001 (Oct. 1984).
Wilson, B., et al., “Human Melanoma-associated Antigens Identified with Monoclonal Antibodies,” La Ricerca Clin. Lab., 12:517-538 (1982).
Loop, S., et al., “Human Tumor-asociated Antigens, p155 and p210, Detected by Monoclonal Antibodies,” Biological Abstracts, vol. 73, Heft 1, p. 431, column 2, Abstract No. 4132 (1982); abstract, Int. J. Cancer, 27(6):775-782 (1981).
Wilson, B., et al., “Distribution and Molecular Characterization of a Cell-Surface and a Cytoplasmic Antigen Detectable in Human Melanoma Cells with Monoclonal Antibodies,” Abstract, Int. J. Cancer, Band 28, pp. 293-300 (1981), abstract, p. 293.
Johnson, J., et al., “Surface Antigens of Human Melanoma Cells Defined by Monoclonal Antibodies, I. Biochemical Characterization of Two Antigens found on Cell Lines and Fresh Tumors of Diverse Tissue Origin,” Eur. Journal Immunology, 11:825-831 (1981).
Houghton, A., et al., “surface Antigens of Melanocytes and Melanomas,” J. Exp. Med., 156:1755-1766 (19820.
Klapdor, R., et al., “Experimental and Clinical Studies with the New Monoclonal Antibody 494132 in Pancreatic Carcinomas,” Digestion, 35(1) 1986.
Mitchell, K., “A Carcinoembryonic Antigen (CEA) Specific Monoclonal Hybridoma Antibody that Reacts only with High-Molecular-Weight CEA,” Chemical Abstracts, 94(17):577, abstract no. 137538s (1981).
Accolla, R., et al., “Monoclonal Antibodies Specific for Carcinoembryonic Antigen and Produced by Two Hybrid Cell Lines,” Proc. Natl Acad. Sci. (USA), 77(1):563-566 (1980).
Wunderlich, M., et al., “Effects or Adjuvant Chemo-or Immunotherapy on the Prognosis of Colorectoal Cancer Operated for Cure,” Br. J. Surg. Suppl.:S107-S110 (1985).
Morrison-Plummer, et al., Journal of Immunological Methods, 64:165-178 (1983).
Cuttitta, et al., Proc. Natl. Acad. Sci., 78(7):4591-4595 (1981).
Kohler, et al., Nature, 256:495-497 (1975).
Hand, et al., Cancer Research, 45:833-840 (1985).
Magnani, et al., Cancer Research, 43:5489-5492 (1983).
Wise, et al., Infection and Immunity, 41(3):1332-1339 (1983).
Waldmann, Science, 252:1657-1662 (1991).
Harris et al., TIBTECH, 11:42-46.
Osband et al., Immunotherapy, 11:193-195 (1990).
Dillman, Ann. Internal. Med., 111:592-603 (1989).
Hird et al., Genes and Cancer, published 1990 by Wiley & Sons Ltd. 17, ed. Carnet et al.
Schmiegal, et al., Cancer Research, 45:1402-1407 (1985).
Chin, et al., Cancer Research, 45:1723-1729 (1985).
Yuan, et al., Cancer Research, 45:6179-6187 (1985).
Campbell, Monoclonal Antibody Technology, chapters 3, 4 and 6 to 10 (Cold Spring Harbor, 1985).
Kohler et al., Eur. J. Immunol., 6:511-519 (1976).
Bosslet et al., Br. J. Cancer, 56(4):516 (1987).
Schulz et al., Br. J. Cancer, 56(4):526 (1987).
Kubel et al., Br. J. Cancer, 56(4):528 (1987).
Campbell, Monoclonal Antibody Technology, pp. 67-101, 120-177, and 180-215 (Elsevier) (1985).
Lutz Riechmann et al., “Reshaping human antibodies for therapy,” Feb. 1988, Nature Vol. 332, pp. 323-327.
Peter Lind et al., “Anti-Carcinoembryonic Antigen Immunoscintigraphy (Technetium-99m-Monoclonal Antibody BW 431/26) and Serum CEA Levels in in Patients with Suspected Primary and Recurrent Colorectal Carcinoma,” Jul. 1991, The Journal of Nuclear Medicine, vol. 32, No. 7, pp. 1319-1325.
P. Benz et al., “Monoclonal antibody BW 431/26 labelled with technetium 99m and indium 111: an investi

Affiliated with

Also associated with

Rating

Monoclonal antibodies (MAbs) against tumor-associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal antibodies (MAbs) against tumor-associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies (MAbs) against tumor-associated... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3498765